Corporate News
LR Health & Beauty SE achieves significant sales growth in the final quarter of 2024 and meets the sales and earnings forecast for the full year 2024
LR Health & Beauty SE achieves significant sales growth in the final quarter of 2024 and meets the sales and earnings forecast for the full year 2024
8.0% increase in sales in Q4 2024 to EUR 76.5 million, confirming growth trend
Full-year sales at EUR 289.2 million, up 4.6% y-o-y
EBITDA reported of EUR 8.3 million in Q4 2024 and EUR 27.3 million in FY 2024 due to one-off charges
Realignment of career plan and successful product launches such as LR ZEITGARD Signature provide positive momentum in 2024 and beyond
Ahlen, 28 February 2025 - LR Health & Beauty SE, Europe’s leading digital social commerce company in the area of high-quality nutritional supplements and cosmetic products, today publishes its figures for the fourth quarter of 2024 as well as preliminary sales and earnings figures for the full year 2024.
LR Health & Beauty SE closed the 2024 financial year with significant sales growth in the fourth quarter, confirming the growth trend of the third quarter. In the fourth quarter of 2024, LR achieved sales (revenue from goods sold) of EUR 76.5 million (Q4 2023: EUR 70.9 million), representing growth of 8.0%. For the full year 2024, LR Health & Beauty SE reports sales of EUR 289.2 million, compared to EUR 276.5 million in the previous year. This corresponds to an increase of 4.6% and is in line with the LR Group’s 2024 sales forecast of EUR 288 to 292 million, which had been raised in November.
“LR Group’s strong growth is confirmation that we are on the right track with our strategy. The positive performance in the final quarter of 2024 is primarily the result of the realignment of the career plan and the successful market launch of further product innovations. We’re constantly working to create the best possible conditions for the business success of our partners, who participated with great enthusiasm in a wide range of kick-off events at the beginning of the year. With LR ZEITGARD Signature, we have perfectly complemented our portfolio in the area of colour cosmetics. We are confident that this solid foundation will enable us to continue our growth trajectory in the year of LR’s 40th anniversary,” says Dr. Andreas Laabs, CEO of LR Health & Beauty SE.
In the fourth quarter of 2024, LR Health & Beauty SE generated EBITDA reported of EUR 8.3 million (Q4 2023: EUR 9.0 million). On a preliminary basis, EBITDA reported for the full year 2024 reached EUR 27.3 million, compared to EUR 31.4 million in 2023 and was therefore in line with the forecast for EBITDA reported adjusted in November to EUR 26 to 29 million. In particular, one-off extraordinary effects related to the realignment of the career plan in the fourth quarter and the early refinancing of the bond in spring 2024 had a negative impact on the earnings development in the financial year. Normalized EBITDA decreased to EUR 9.5 million in the fourth quarter of 2024, compared to EUR 10.2 million in the fourth quarter of the previous year. In the full year 2024, normalized EBITDA reached EUR 32.6 million on a preliminary basis (2023: EUR 35.4 million).
Valdemaras Gordinskis, Vice President Global Controlling and Investor Relations at LR Health & Beauty SE, comments: “In 2025, we will continue to focus on implementing further strategic measures. For example, we are stepping up the development of new product innovations in order to expand our range of high-quality nutritional supplements and cosmetic products. We will also focus on increasing the efficiency and profitability of the LR Group through operational improvements in production and logistics as well as the further digitalization of our sales activities.”
The report for the fourth quarter of 2024 is available online from today on the company website at https://ir.lrworld.com/. The final, audited figures for the 2024 financial year will be published on the company website at the end of April 2025, together with the annual report.
* As issuer of the New Bond 2024/2028, LR Health & Beauty SE publishes the figures for the fourth quarter and the full year 2024 and for the relevant periods in the previous year. The previous year’s figures for 2023 may differ from the figures for 2023 published previously by LR Global Holding GmbH.
LR Group
Following the motto "More quality for your life" the LR Group with headquarters in Ahlen/Westphalia successfully produces and markets various high-quality nutritional supplements and cosmetic products in 32 countries. As an attractive social commerce company, LR supports the personal exchange in its community with efficient, digital solutions. The holistic tool "LR neo" offers the international partnership all business-relevant key figures and information for their LR business in one dashboard.
LR has been firmly established on the market since 1985 as a "people business" company that focuses on people and personal advice. In times of changing working environments, the business model particularly appeals to those who are looking for more flexibility, a better work-life balance and greater financial independence.
The processing of Aloe Vera has been one of the core competencies of LR for more than 20 years. Only the valuable inside of the leaf is used for the products. In Ahlen, the company has established one of the most modern Aloe Vera production sites for Aloe Vera Drinking Gels in Europe.
In autumn 2009, LR founded the LR Global Kids Fund e.V., which supports deprived children and their families in many countries around the world efficiently and unbureaucratically in cooperation with local institutions. For further information on our commitment to sustainability, please read our sustainability report.
LR currently has around 1,200 employees and hundreds of thousands of registered community members.
Your Contacts:
PR Contact:
LR Health & Beauty SE
Almut Kellermeyer
Head of Corporate Communication
Kruppstraße 55
59227 Ahlen
Phone: +49(0)2382 7813-106
E-Mail: a.kellermeyer@LRworld.com
https://ir.lrworld.com/
IR Contact:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Gebäude D
65195 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-Mail: burbach@cometis.de
LR Health & Beauty SE publishes bond prospectus and applies for admission to trading of bonds on the corporate bond list of Nasdaq Stockholm
LR Health & Beauty SE publishes bond prospectus and applies for admission to trading of bonds on the corporate bond list of Nasdaq Stockholm
Ahlen, 26 February 2025 – On 4 March 2024, LR Health & Beauty SE (“LR SE”) issued senior secured floating rate bonds (2024/2028) in an amount of EUR 130,000,000 (the “Bonds”). Under the terms and conditions for the Bonds, LR SE has undertaken to apply for admission to trading of the Bonds on the corporate bond list of Nasdaq Stockholm. For the purpose of the admission to trading, LR SE has prepared a listing prospectus which has been approved by the Swedish Financial Supervisory Authority today. LR SE will submit an application for admission to trading of the Bonds and the first trading day on Nasdaq Stockholm is expected to be on or about 28 February 2025.
The prospectus will be available at LR Group’s website, ir.lrworld.com/en/bond/ and the Swedish Financial Supervisory Authority’s website www.fi.se.
LR Group
Following the motto "More quality for your life" the LR Group with headquarters in Ahlen/Westphalia successfully produces and markets various high-quality nutritional supplements and cosmetic products in 32 countries. As an attractive social commerce company, LR supports the personal exchange in its community with efficient, digital solutions. The holistic tool "LR neo" offers the international partnership all business-relevant key figures and information for their LR business in one dashboard.
LR has been firmly established on the market since 1985 as a "people business" company that focuses on people and personal advice. In times of changing working environments, the business model particularly appeals to those who are looking for more flexibility, a better work-life balance and greater financial independence.
The processing of Aloe Vera has been one of the core competencies of LR for more than 20 years. Only the valuable inside of the leaf is used for the products. In Ahlen, the company has established one of the most modern Aloe Vera production sites for Aloe Vera Drinking Gels in Europe.
In autumn 2009, LR founded the LR Global Kids Fund e.V., which supports deprived children and their families in many countries around the world efficiently and unbureaucratically in cooperation with local institutions. For further information on our commitment to sustainability, please read our sustainability report.
LR currently has around 1,200 employees and hundreds of thousands of registered community members.
Your Contacts:
PR Contact:
LR Health & Beauty SE
Almut Kellermeyer
Head of Corporate Communication
Kruppstraße 55
59227 Ahlen
Phone: +49(0)2382 7813-106
E-Mail: a.kellermeyer@LRworld.com
https://ir.lrworld.com/
IR Contact:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Gebäude D
65195 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-Mail: burbach@cometis.de
LR Health & Beauty SE further increases growth trend in the third quarter
LR Health & Beauty SE further increases growth trend in the third quarter
- Sales significantly increased by 7.2% to EUR 69.4 million in the third quarter of 2024
- In Q3 2024 EBITDA reported rose to EUR 7.3 million and normalized EBITDA increased to EUR 8.7 million
- Successful market launch of LR ZEITGARD Signature and realignment of the career plan increased the number of new distributors and led to higher sales
- Adjusted guidance for 2024: Sales range of EUR 288 million to EUR 292 million, EBITDA reported in the corridor of EUR 26 million to EUR 29 million
Ahlen, 26 November 2024 – LR Health & Beauty SE, Europe’s leading digital social commerce company in the area of high-quality nutritional supplements and cosmetic products, today published its figures for the third quarter of 2024 and the first nine months of 2024. Despite the challenging market environment, LR Health & Beauty SE increased sales (revenue from goods sold) by 7.2% to EUR 69.4 million in the third quarter of 2024 (Q3 2023: EUR 64.7 million). This resulted in sales for the first nine months of 2024 of EUR 212.7 million compared to EUR 205.6 million in the previous year, an increase of 3.4%. The recent market launch of the cosmetic product range LR ZEITGARD Signature and the realignment of the career plan for distributors made a major contribution to sales growth.
On top of that, EBITDA reported increased in the third quarter of 2024 to EUR 7.3 million compared to EUR 7.1 million in the third quarter of the previous year. As a result, EBITDA reported in the first nine months of 2024 totaled EUR 19.0 million compared to EUR 22.4 million in the prior year period. Normalized EBITDA increased sharply from EUR 7.7 million in the third quarter of the previous year to EUR 8.7 million in the third quarter of 2024, resulting in a figure for the first nine months of EUR 23.1 million (9M 2023: EUR 25.2 million).
Dr. Andreas Laabs, CEO of LR Health & Beauty SE, comments: "With the introduction of the new LR ZEITGARD Signature product category, we have achieved one of the most successful product launches in LR's history and seamlessly continued our journey of successful market launches of the recent past. In addition, we have further improved the attractiveness of our business model for distributors by realigning our career plan. We are currently experiencing a decent influx of new distributors and a significant increase in the number of successful careers. Accordingly, we are looking forward to continuing to grow significantly in 2024 and believe we are ideally positioned for an even more successful 2025.“
Based on the business results for the first nine months of 2024 and the realignment of the career plan for distributors in the third quarter of 2024, LR Health & Beauty SE is adjusting its forecast for sales and EBITDA reported for the full year 2024. LR Health & Beauty SE is increasing the sales guidance for the 2024 financial year and now expects a sales corridor of EUR 288 million to EUR 292 million. Management originally assumed that sales (revenue from goods sold) would be at the previous year's level (2023: EUR 276.5 million). The company is also adjusting its earnings expectations for 2024 and revising its forecast for EBITDA reported to be in the range of EUR 26 million to EUR 29 million. Originally, management expected a slightly lower to stable EBITDA figure year-on-year (2023: EUR 31.4 million). The underlying reason is that the realignment of the career plan for distributors in the third and fourth quarters of 2024 will lead to a significant increase in distributors, which will have a positive impact on sales development. At the same time, the result is burdened by refinancing costs incurred and, above all, by one-off, extraordinary effects in the low single-digit million euro range due to changes to the distributors' career plan.
Valdemaras Gordinskis, Vice President Global Controlling and Investor Relations of LR Health & Beauty SE, explains: “With the realignment of the career plan, we have set an important course for sustainable profitable growth. This is likely to result in one-off, extraordinary effects in the fourth quarter, which will have a negative impact on earnings. However, in the financial year 2025 this will yield positive effects on sales and profitability.“
With the new logistics centre at the Ahlen site, which was put into operation in October 2024, LR sets the course for future growth. A state-of-the-art warehouse system will ensure efficiency gains and improve scaling possibilities.
The full report for the first nine months of the financial year 2024 is available online from today on the company website at https://ir.lrworld.com/.
* As issuer of the New Bond 2024/2028, LR Health & Beauty SE publishes the figures for the third quarter and the first nine months of financial year 2024 and for the relevant periods in the previous year. The previous year’s figures for 2023 may differ from the figures for 2023 published previously by LR Global Holding GmbH.
LR Group
Following the motto "More quality for your life" the LR Group with headquarters in Ahlen/Westphalia successfully produces and markets various high-quality nutritional supplements and cosmetic products in 32 countries. As an attractive social commerce company, LR supports the personal exchange in its community with efficient, digital solutions. The holistic tool "LR neo" offers the international partnership all business-relevant key figures and information for their LR business in one dashboard.
LR has been firmly established on the market since 1985 as a "people business" company that focuses on people and personal advice. In times of changing working environments, the business model particularly appeals to those who are looking for more flexibility, a better work-life balance and greater financial independence.
The processing of Aloe Vera has been one of the core competencies of LR for more than 20 years. Only the valuable inside of the leaf is used for the products. In Ahlen, the company has established one of the most modern Aloe Vera production sites for Aloe Vera Drinking Gels in Europe.
In autumn 2009, LR founded the LR Global Kids Fund e.V., which supports deprived children and their families in many countries around the world efficiently and unbureaucratically in cooperation with local institutions. For further information on our commitment to sustainability, please read our sustainability report.
LR currently has around 1,200 employees and hundreds of thousands of registered community members.
Your Contacts:
PR Contact:
LR Health & Beauty SE
Almut Kellermeyer
Head of Corporate Communication
Kruppstraße 55
59227 Ahlen
Phone: +49(0)2382 7813-106
E-Mail: a.kellermeyer@LRworld.com
https://ir.lrworld.com/
IR Contact:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Gebäude D
65195 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-Mail: burbach@cometis.de
Ad-hoc Announcements
LR GLOBAL HOLDING GMBH GIVES NOTICE OF CONDITIONAL VOLUNTARY TOTAL REDEMPTION OF ITS OUTSTANDING 2021/2025 BONDS AND LR HEALTH & BEAUTY SE ISSUES NEW SENIOR SECURED BONDS OF EUR 130 MILLION
NOT FOR PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, CYPRUS, HONG KONG, ITALY, JAPAN, NEW ZEALAND, SOUTH AFRICA, THE UNITED KINGDOM OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD REQUIRE ANY FURTHER MEASURES FROM LR GLOBAL HOLDING GMBH, LR HEALTH & BEAUTY SE, PARETO SECURITIES AS, FRANKFURT BRANCH, ARCTIC SECURITIES AS OR ANY OTHER PARTY.
Disclosure of an inside information acc. to Art. 17 of the Regulation (EU) No. 596/2014 (Market Abuse Regulation – MAR)
LR GLOBAL HOLDING GMBH GIVES NOTICE OF CONDITIONAL VOLUNTARY TOTAL REDEMPTION OF ITS OUTSTANDING 2021/2025 BONDS AND LR HEALTH & BEAUTY SE ISSUES NEW SENIOR SECURED BONDS OF EUR 130 MILLION
Ahlen, 19 February 2024 – LR Global Holding GmbH (the “Company”) gives conditional notice of voluntary total redemption of its outstanding EUR 125 million senior secured 2021/2025 bonds with ISIN NO0010894850 (the “Existing Bonds”) in full and announces that the Company’s parent company LR Health & Beauty SE has, following a successfull book building process, placed new senior secured bonds with ISIN NO0013149658 due in 2028 with a nominal amount of EUR 130 million (the ”New Bonds”) and generating proceeds of approximately EUR 125 million.
A notice of a conditional voluntary total redemption of the Existing Bonds will be sent to Verdipapirsentralen ASA (Euronext Securities Oslo) (“VPS”) for delivery to persons registered in the securities account with VPS as holders of Existing Bonds.
The redemption is conditional upon successful settlement of the New Bonds and the receipt of the proceeds from the New Bonds by the Company from a designated escrow account prior to the lapse of 7 March 2024 (the “Condition”). Should the Condition not be fulfilled by the lapse of 7 March 2024, the redemption will not occur (unless the Condition has been waived by the Company at its sole discretion) which will, in such case, be communicated by the Company through a subsequent announcement.
Subject to the fulfilment or waiver of the Condition, the date for redemption is set at 11 March 2024 and the record date for the redemption will be 7 March 2024, i.e. two business days prior to the redemption date. The Existing Bonds will then be redeemed at an amount equal to 101.45 % of the total outstanding nominal amount (i.e., EUR 1,014.50 per Existing Bond) together with any unpaid interest accrued until but excluding the redemption date.
In connection with the redemption, the Existing Bonds will be delisted from Frankfurt Stock Exchange and Nasdaq Stockholm.
The New Bonds will have a term of 4 years and will carry a floating rate coupon of 3 months EURIBOR plus 7.5 % per annum. The Company intends to apply for admission to trading of the Bonds on the Open Market of the Frankfurt Stock Exchange and the corporate bond list of Nasdaq Stockholm.
This announcement is for information purposes only and is not to be construed as an offer to purchase or sell or a solicitation of an offer to purchase or sell with respect to any securities of the Company or LR Health & Beauty SE.
IR contact:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Gebäude D
65195 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-mail: burbach@cometis.de
This information is information that LR Global Holding GmbH is obliged to make public pursuant to the EU Market Abuse Regulation (EU 596/2014). The information in this publication has been made public through the agency of the responsible person set out above for publication at the time stated by the Company's news distributor, EQS Group AG, at the time of publication.
Important Note
THE SECURITIES MENTIONED HEREIN HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE US SECURITIES ACT. THEY MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES, EXCEPT PURSUANT TO AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT. NO PUBLIC OFFERING WILL BE MADE IN THE UNITED STATES AND THE INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE AN OFFER TO SELL NOR A SOLICITATION TO BUY OR SUBSCRIBE FOR SECURITIES OF LR GLOBAL HOLDING GMBH AND/OR LR HEALTH & BEAUTY SE AND NO EXCHANGE OFFER IS BEING MADE IN THE UNITED STATES, AUSTRALIA, CANADA, CYPRUS, HONG KONG, ITALY, JAPAN, NEW ZEALAND, SOUTH AFRICA, THE UNITED KINGDOM OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION/SUCH OFFER WOULD REQUIRE ANY FURTHER MEASURES FROM LR GLOBAL HOLDING GMBH, LR HEALTH & BEAUTY SE, PARETO SECURITIES AS, FRANKFURT BRANCH, ARCTIC SECURITIES AS OR ANY OTHER PARTY OR BE PROHIBITED BY APPLICABLE LAW.
LR GLOBAL HOLDING GMBH ANNOUNCES ITS INTENTION TO EXERCISE THE CALL-OPTION TO REDEEM ITS OUTSTANDING 2021/2025 BONDS SUBJECT TO A SENIOR SECURED BOND ISSUANCE BY LR HEALTH & BEAUTY SE WITH A TARGET VOLUME OF EUR 125 MILLION
NOT FOR PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, CYPRUS, HONG KONG, ITALY, JAPAN, NEW ZEALAND, SOUTH AFRICA, THE UNITED KINGDOM OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD REQUIRE ANY FURTHER MEASURES FROM LR GLOBAL HOLDING GMBH, LR HEALTH & BEAUTY SE, PARETO SECURITIES AS, FRANKFURT BRANCH, ARCTIC SECURITIES AS OR ANY OTHER PARTY.
Disclosure of an inside information acc. to Art. 17 of the Regulation (EU) No. 596/2014 (Market Abuse Regulation – MAR)
LR GLOBAL HOLDING GMBH ANNOUNCES ITS INTENTION TO EXERCISE THE CALL-OPTION TO REDEEM ITS OUTSTANDING 2021/2025 BONDS SUBJECT TO A SENIOR SECURED BOND ISSUANCE BY LR HEALTH & BEAUTY SE WITH A TARGET VOLUME OF EUR 125 MILLION
Ahlen, 13 February 2024 – LR Global Holding GmbH (the “Company”) announces that the Company contemplates a refinancing of the Company’s outstanding EUR 125,000,000 senior secured 2021/2025 bonds with ISIN NO0010894850 (the “Existing Bonds”), subject to an issue of a new senior secured corporate bond under Swedish law (Nordic Bond) with a target volume of EUR 125,000,000 (the ”New Bonds”) by the Company’s parent company LR Health & Beauty SE.
LR Health & Beauty SE has mandated Pareto Securities AS, Frankfurt Branch and Arctic Securities AS as joint bookrunners to arrange credit investor meetings in connection with the issue of the New Bonds. A capital markets transaction may follow, subject to market conditions.
Subject to the successful issuance of the New Bonds and the receipt of the required net proceeds from such issuance, the Company intends to mainly use these proceeds to exercise its call-option and redeem in full the EUR 125,000,000 outstanding amount of its Existing Bonds. In accordance with the terms and conditions, the Existing Bonds due 2025 would be redeemed at a redemption price of 101.45 %, plus accrued and unpaid interest thereon up to, but excluding, the redemption date.
This announcement is not a redemption notice in accordance with the terms and conditions of the Existing Bonds, and such redemption notice will be given by the Company only upon a successful placement of the New Bonds on the basis of a book-building process.
IR contact:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Gebäude D
65195 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-mail: burbach@cometis.de
This information is information that LR Global Holding GmbH is obliged to make public pursuant to the EU Market Abuse Regulation (EU 596/2014). The information in this publication has been made public through the agency of the responsible person set out above for publication at the time stated by the Company's news distributor, EQS Group AG, at the time of publication.
Important Note
THE SECURITIES MENTIONED HEREIN HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE US SECURITIES ACT. THEY MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES, EXCEPT PURSUANT TO AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT. NO PUBLIC OFFERING WILL BE MADE IN THE UNITED STATES AND THE INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE AN OFFER TO SELL NOR A SOLICITATION TO BUY OR SUBSCRIBE FOR SECURITIES OF LR GLOBAL HOLDING GMBH AND/OR LR HEALTH & BEAUTY SE AND NO EXCHANGE OFFER IS BEING MADE IN THE UNITED STATES, AUSTRALIA, CANADA, CYPRUS, HONG KONG, ITALY, JAPAN, NEW ZEALAND, SOUTH AFRICA, THE UNITED KINGDOM OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION/SUCH OFFER WOULD REQUIRE ANY FURTHER MEASURES FROM LR GLOBAL HOLDING GMBH, LR HEALTH & BEAUTY SE, PARETO SECURITIES AS, FRANKFURT BRANCH, ARCTIC SECURITIES AS OR ANY OTHER PARTY OR BE PROHIBITED BY APPLICABLE LAW.
Dr. Andreas Laabs becomes new chairman of the management board of the LR Group as successor for Andreas Friesch
Disclosure of an inside information acc. to Article 17 of the Regulation (EU) No 596/2014
Dr. Andreas Laabs becomes new chairman of the management board of the LR Group as successor for Andreas Friesch
Ahlen, 23 May 2022 – LR Global Holding GmbH ("Company") as the issuer of the bonds (WKN: A3H3FM / ISIN: NO0010894850) informs about the fact that Dr. Andeas Laabs, currently CFO and COO of the Company, will become the new chairman of the management board of LR Health & Beauty SE as well as CEO of the Company. The current chairman of the management board, Andreas Friesch, will for personal reasons by mutual agreement resign as chairman of the management board of LR Health& Beauty SE as well as managing director/CEO of the Company and will leave the LR Group on 27 May 2022.
IR Contact:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Building D
65195 Wiesbaden
Tel.: +49 (0)611 - 205855-23
Fax: +49 (0)611 - 205855-66
E-Mail: burbach@cometis.de
Directors‘ Dealings
At the moment no news are available.